Please select your Region.
Please select your Region.
Oct 30, 2012
ARKRAY, Inc. (herein ARKRAY) has established a sales office in Indonesia (PT. ARKRAY) which will begin operations on 6 November.
ARKRAY operates facilities in 10 countries and distributes its products to over 80 nations. In Asia, ARKRAY has sales offices in China, South Korea and India and seeks to further extend its business reach in the area.
ARKRAY has established this new office in Indonesia to serve as a business platform, with an eye on accelerated expansion into global markets and an increased presence in the thriving South East Asian region.
In FY2011, Indonesia showed continued strong GDP growth figures of 6.5% and is gaining attention as a developing force following closely behind the BRICS. With 240 million people, it has the largest population of any ASEAN country.
It currently has an in vitro diagnostics market worth approximately 7.9 billion yen1) with the highest growth rate among ASEAN. The size of this market is expected to grow in line with economic development in the country.
Indonesia has the 6th largest diabetic population with 7.29 million people affected by the disease. This is expected to grow to 11.8 million diabetics by 2030.2)
ARKRAY is seeking to capture a share of this growing market in Indonesia by establishing a sales network for diabetes tests, general medical tests and biochemical test systems as well as offering improved services to customers.
1) Report from Frost & Sullivan (FY2011)
2) Report from International Diabetes Federation (FY2011)
Company name | PT. ARKRAY |
---|---|
Address | Mega Plaza, 12th Floor, Jl. HR. Rasuna Said Kav. C-3, Jakarta 12920, INDONESIA |
Start of business | 6 November 2012 |
Nature of business | Sale of and customized services for sample test instruments and in vitro diagnostic reagents |